Skip to main content

ABI, Myriad Proteomics Pen R&D Collaboration

NEW YORK, Aug. 13 - Applied Biosystems and Myriad Proteomics today said they will collaborate to develop new proteomics technology.

 

The deal will employ the companies' existing capabilities, such as ABI's mass spectrometry and Myriad's experience with protein-protein interactions, to devise more effective ways of analyzing proteins and map the human proteome.

 

In the process ABI will have its 4700 protein analyzer put through its paces in hopes of tweaking its performance in protein-protein-interaction studies, said Stephen Martin, director of ABI's protein research center.

 

Participating in the collaboration will be scientists from ABI's Framingham, Wash., facility, and Myriad Proteomics' new space in Salt Lake City, the companies said. Myriad Proteomics was founded by Myriad Genetics, Oracle, Hitachi, and Friedli Corporate Finance.

 

Click here for more information.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.